Stereotactic Body Radiation Therapy for the Treatment of Locally Recurrent and Oligoprogressive Non-Small Cell Lung Cancer: A Single Institution Experience
ObjectivesTo investigate the efficacy and safety of lung stereotactic body radiation therapy (SBRT) for non-small cell lung cancer (NSCLC) including oligorecurrent and oligoprogressive disease.MethodsSingle-institution retrospective analysis of 60 NSCLC patients with 62 discrete lesions treated with...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.870143/full |
| _version_ | 1818006339262087168 |
|---|---|
| author | Leah M. Katz Victor Ng S. Peter Wu Sherry Yan David Grew Samuel Shin Nicholas W. Colangelo Allison McCarthy Harvey I. Pass Abraham Chachoua Peter B. Schiff |
| author_facet | Leah M. Katz Victor Ng S. Peter Wu Sherry Yan David Grew Samuel Shin Nicholas W. Colangelo Allison McCarthy Harvey I. Pass Abraham Chachoua Peter B. Schiff |
| author_sort | Leah M. Katz |
| collection | DOAJ |
| description | ObjectivesTo investigate the efficacy and safety of lung stereotactic body radiation therapy (SBRT) for non-small cell lung cancer (NSCLC) including oligorecurrent and oligoprogressive disease.MethodsSingle-institution retrospective analysis of 60 NSCLC patients with 62 discrete lesions treated with SBRT between 2008 and 2017. Patients were stratified into three groups, including early stage, locally recurrent, and oligoprogressive disease. Group 1 included early stage local disease with no prior local therapy. Group 2 included locally recurrent disease after local treatment of a primary lesion, and group 3 included regional or well-controlled distant metastatic disease receiving SBRT for a treatment naive lung lesion (oligoprogressive disease). Patient/tumor characteristics and adverse effects were recorded. Local failure free survival (LFFS), progression free survival (PFS), and overall survival (OS) were estimated using the Kaplan Meier method.ResultsAt median follow-up of 34 months, 67% of the study population remained alive. The estimated 3-year LFFS for group 1, group 2, and group 3 patients was 95% (95% CI: 86%-100%), 82%(62% - 100%), and 83% (58-100%), respectively. The estimated 3-year PFS was 59% (42-83%), 40% (21%-78%), and 33% (12%-95%), and the estimated 3-year OS was 58% (41-82%), 60% (37-96%), and 58% (31-100%)), respectively for each group. When adjusted for age and size of lesion, no significant difference in OS, LFFS, and PFS emerged between groups (p > 0.05). No patients experienced grade 3 to 5 toxicity. Eighteen patients (29%) experienced grade 1 to 2 toxicity. The most common toxicities reported were cough and fatigue.ConclusionsOur data demonstrates control rates in group 1 patients comparable to historical controls. Our study also reveals comparable clinical results for SBRT in the treatment of NSCLC by demonstrating similar rates of LFFS and OS in group 2 and group 3 patients with locally recurrent and treatment naïve lung lesion with well-controlled distant metastatic disease. |
| first_indexed | 2024-04-14T05:00:39Z |
| format | Article |
| id | doaj.art-5e041cac3eff420f931de82b88a4f085 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-14T05:00:39Z |
| publishDate | 2022-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-5e041cac3eff420f931de82b88a4f0852022-12-22T02:10:59ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-05-011210.3389/fonc.2022.870143870143Stereotactic Body Radiation Therapy for the Treatment of Locally Recurrent and Oligoprogressive Non-Small Cell Lung Cancer: A Single Institution ExperienceLeah M. Katz0Victor Ng1S. Peter Wu2Sherry Yan3David Grew4Samuel Shin5Nicholas W. Colangelo6Allison McCarthy7Harvey I. Pass8Abraham Chachoua9Peter B. Schiff10Department of Radiation Oncology, New York University (NYU) Langone Health, Perlmutter Cancer Center, New York, NY, United StatesDepartment of Radiation Oncology, New York University (NYU) Langone Health, Perlmutter Cancer Center, New York, NY, United StatesDepartment of Radiation Oncology, New York University (NYU) Langone Health, Perlmutter Cancer Center, New York, NY, United StatesDepartment of Radiation Oncology, New York University (NYU) Langone Health, Perlmutter Cancer Center, New York, NY, United StatesDepartment of Radiation Oncology, New York University (NYU) Langone Health, Perlmutter Cancer Center, New York, NY, United StatesDepartment of Radiation Oncology, New York University (NYU) Langone Health, Perlmutter Cancer Center, New York, NY, United StatesDepartment of Radiation Oncology, New York University (NYU) Langone Health, Perlmutter Cancer Center, New York, NY, United StatesDepartment of Radiation Oncology, New York University (NYU) Langone Health, Perlmutter Cancer Center, New York, NY, United StatesDepartment of Cardiothoracic Surgery, New York University (NYU) Langone Health, Perlmutter Cancer Center, New York, NY, United StatesDepartment of Medicine, Division of Medical Oncology, New York University (NYU) Langone Health, Perlmutter Cancer Center, New York, NY, United StatesDepartment of Radiation Oncology, New York University (NYU) Langone Health, Perlmutter Cancer Center, New York, NY, United StatesObjectivesTo investigate the efficacy and safety of lung stereotactic body radiation therapy (SBRT) for non-small cell lung cancer (NSCLC) including oligorecurrent and oligoprogressive disease.MethodsSingle-institution retrospective analysis of 60 NSCLC patients with 62 discrete lesions treated with SBRT between 2008 and 2017. Patients were stratified into three groups, including early stage, locally recurrent, and oligoprogressive disease. Group 1 included early stage local disease with no prior local therapy. Group 2 included locally recurrent disease after local treatment of a primary lesion, and group 3 included regional or well-controlled distant metastatic disease receiving SBRT for a treatment naive lung lesion (oligoprogressive disease). Patient/tumor characteristics and adverse effects were recorded. Local failure free survival (LFFS), progression free survival (PFS), and overall survival (OS) were estimated using the Kaplan Meier method.ResultsAt median follow-up of 34 months, 67% of the study population remained alive. The estimated 3-year LFFS for group 1, group 2, and group 3 patients was 95% (95% CI: 86%-100%), 82%(62% - 100%), and 83% (58-100%), respectively. The estimated 3-year PFS was 59% (42-83%), 40% (21%-78%), and 33% (12%-95%), and the estimated 3-year OS was 58% (41-82%), 60% (37-96%), and 58% (31-100%)), respectively for each group. When adjusted for age and size of lesion, no significant difference in OS, LFFS, and PFS emerged between groups (p > 0.05). No patients experienced grade 3 to 5 toxicity. Eighteen patients (29%) experienced grade 1 to 2 toxicity. The most common toxicities reported were cough and fatigue.ConclusionsOur data demonstrates control rates in group 1 patients comparable to historical controls. Our study also reveals comparable clinical results for SBRT in the treatment of NSCLC by demonstrating similar rates of LFFS and OS in group 2 and group 3 patients with locally recurrent and treatment naïve lung lesion with well-controlled distant metastatic disease.https://www.frontiersin.org/articles/10.3389/fonc.2022.870143/fullstereotactic body radiation therapy (SBRT)oligometastasisNSLClung cancerradiation therapy |
| spellingShingle | Leah M. Katz Victor Ng S. Peter Wu Sherry Yan David Grew Samuel Shin Nicholas W. Colangelo Allison McCarthy Harvey I. Pass Abraham Chachoua Peter B. Schiff Stereotactic Body Radiation Therapy for the Treatment of Locally Recurrent and Oligoprogressive Non-Small Cell Lung Cancer: A Single Institution Experience Frontiers in Oncology stereotactic body radiation therapy (SBRT) oligometastasis NSLC lung cancer radiation therapy |
| title | Stereotactic Body Radiation Therapy for the Treatment of Locally Recurrent and Oligoprogressive Non-Small Cell Lung Cancer: A Single Institution Experience |
| title_full | Stereotactic Body Radiation Therapy for the Treatment of Locally Recurrent and Oligoprogressive Non-Small Cell Lung Cancer: A Single Institution Experience |
| title_fullStr | Stereotactic Body Radiation Therapy for the Treatment of Locally Recurrent and Oligoprogressive Non-Small Cell Lung Cancer: A Single Institution Experience |
| title_full_unstemmed | Stereotactic Body Radiation Therapy for the Treatment of Locally Recurrent and Oligoprogressive Non-Small Cell Lung Cancer: A Single Institution Experience |
| title_short | Stereotactic Body Radiation Therapy for the Treatment of Locally Recurrent and Oligoprogressive Non-Small Cell Lung Cancer: A Single Institution Experience |
| title_sort | stereotactic body radiation therapy for the treatment of locally recurrent and oligoprogressive non small cell lung cancer a single institution experience |
| topic | stereotactic body radiation therapy (SBRT) oligometastasis NSLC lung cancer radiation therapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.870143/full |
| work_keys_str_mv | AT leahmkatz stereotacticbodyradiationtherapyforthetreatmentoflocallyrecurrentandoligoprogressivenonsmallcelllungcancerasingleinstitutionexperience AT victorng stereotacticbodyradiationtherapyforthetreatmentoflocallyrecurrentandoligoprogressivenonsmallcelllungcancerasingleinstitutionexperience AT speterwu stereotacticbodyradiationtherapyforthetreatmentoflocallyrecurrentandoligoprogressivenonsmallcelllungcancerasingleinstitutionexperience AT sherryyan stereotacticbodyradiationtherapyforthetreatmentoflocallyrecurrentandoligoprogressivenonsmallcelllungcancerasingleinstitutionexperience AT davidgrew stereotacticbodyradiationtherapyforthetreatmentoflocallyrecurrentandoligoprogressivenonsmallcelllungcancerasingleinstitutionexperience AT samuelshin stereotacticbodyradiationtherapyforthetreatmentoflocallyrecurrentandoligoprogressivenonsmallcelllungcancerasingleinstitutionexperience AT nicholaswcolangelo stereotacticbodyradiationtherapyforthetreatmentoflocallyrecurrentandoligoprogressivenonsmallcelllungcancerasingleinstitutionexperience AT allisonmccarthy stereotacticbodyradiationtherapyforthetreatmentoflocallyrecurrentandoligoprogressivenonsmallcelllungcancerasingleinstitutionexperience AT harveyipass stereotacticbodyradiationtherapyforthetreatmentoflocallyrecurrentandoligoprogressivenonsmallcelllungcancerasingleinstitutionexperience AT abrahamchachoua stereotacticbodyradiationtherapyforthetreatmentoflocallyrecurrentandoligoprogressivenonsmallcelllungcancerasingleinstitutionexperience AT peterbschiff stereotacticbodyradiationtherapyforthetreatmentoflocallyrecurrentandoligoprogressivenonsmallcelllungcancerasingleinstitutionexperience |